concentrated oral gel

(redirected from Gelclair)

concentrated oral gel



(trade name)


Therapeutic: oral protectants
Pregnancy Category: UK


Management of oral pain due to:
  • oral mucositis/stomatitis (from chemotherapy or radiation),
  • irritation due to oral surgery,
  • traumatic ulcers caused by braces or poorly fitted dentures,
  • diffuse aphthous ulcers,
  • mouth ulcers caused by other diseases.


Adheres to oral mucosal surface, providing a protective mechanical barrier over ulcerated areas.

Therapeutic effects

Decreased pain from oral ulcers.


Absorption: Action is local.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (protectant effect)

POrapidunknownas long as application remains on oral surface


Contraindicated in: Hypersensitivity.
Use Cautiously in: None.

Adverse Reactions/Side Effects

None noted


Drug-Drug interaction



Oral (Adults) Use one packet 3 times daily, or as needed.


Concentrated oral gel: 15 mL packets in box of 21 packets

Nursing implications

Nursing assessment

  • Assess mouth ulcers prior to and periodically during therapy.
  • Assess severity of pain prior to and periodically during therapy.

Potential Nursing Diagnoses

Acute pain (Indications)


  • Pour entire contents of single-dose packet into glass and add 15 mL or 1 tbsp of water. If mixture is too thick, add additional 15–30 mL of water to achieve desired consistency. Stir well and use at once. Store at room temperature; do not refrigerate. Gel may become darker or thicker over time, but this does not affect efficacy or safety. Do not use packets that are split or torn or beyond expiration date.
  • If water is not available, may be used undiluted.
  • Oral: Administer 3 times daily or as needed.

Patient/Family Teaching

  • Instruct patient on preparing and using Gelclair. Rinse around mouth for at least 1 min or as long as possible to coat tongue, palate, throat, inside of cheeks, and all oral tissue thoroughly. Gargle and spit out. Advise patient that no adverse effects are expected if Gelclair is swallowed accidently. Instruct patient not to eat or drink for at least 1 hr after treatment.
  • Instruct patient to keep product out of direct sunlight and to store at room temperature.

Evaluation/Desired Outcomes

  • Decrease in pain from oral ulcers. If no improvement in 7 days, notify health care professional.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Midatech Pharma plc (AIM: MTPH) (Nasdaq: MTP) has enrolled the first patient in its Gelclair Phase IV trial in stem cell transplant (SCT), the pharmaceutical company said on Friday.
Polyvinylpyrrolidone-sodium sodium hyaluronate gel (Gelclair) kullaniminin allojenik kok hucre transplantasyonu yapilan ve oral mukoziti olan hastalarda (n=37) oral kavitede mikrobiyal kolonizasyona etkisini ve toleransini degerlendirmek amaciyla yapilan bir calismada, Gelclair'in gunde en az 3 kez kullaniminin klorheksidin, benzymanine, salvia kullananlara gore oral kavitede mikrobial kolonizasyonu ozellikle Enterococcus ve Candida kolonizasyonunu azalttigi, etki suresinin de daha uzun oldugu (mukozada olumlu etkisinin) saptanmistir.
Gelclair is a concentrated gel, and Zilactin is a protective film.
In these cases, a prescription product called Gelclair may be recommended.
DARA holds exclusive US marketing rights to Gelclair oral rinse gel, Oravig (miconazole) buccal tablets and Soltamox (tamoxifen citrate oral liquid solution).
It was reported on Friday that the contract has been signed for both Gelclair, an FDA-approved bioadherent oral rinse gel for treating the painful symptoms of oral mucositis, and Soltamox (tamoxifen citrate) oral liquid solution, to be accessible to RainTree's Nationwide Oncology Membership.
US-based oncology company DARA BioSciences Inc (NasdaqCM:DARA) reported on Thursday the execution of a pharmacy supply agreement for Gelclair and Soltamox with RainTree Oncology Services.
According to the agreement and a shared sales force agreement with Mission, in addition to promoting Dara's products Soltamox (tamoxifen citrate), Gelclair and Bionect, the Alamo sales team will also carry three Mission Pharmacal products: Ferralet 90 (for anemia), BINOSTO (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis), and Aquoral (for chemotherapy/radiation therapy-induced dry mouth).
Net proceeds will be used by DARA BioSciences Inc to fund expenses related to the commercialisation of its complementary portfolio of oncology and oncology supportive care pharmaceutical products, including expenses for the commercial activities related to Soltamox, Gelclair and Bionect and for working capital, business development and other general corporate purposes.
27 April 2010 - Switzerland-based pharmaceutical group Helsinn and Vifor Pharma announced yesterday that they have signed a distribution and licensing agreement for Helsinn's product Gelclair in Switzerland.